{
    "nctId": "NCT00488722",
    "briefTitle": "A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer",
    "officialTitle": "A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": "N/A",
    "primaryOutcomeMeasure": "To evaluate the efficacy of concurrent Zoladex and CEF as neoadjuvant regimen in terms of: ORR(CR+PR) and PCR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent\n2. Pathological confirmation of breast cancer\n3. Tumor stage(TNM):T2-4bN0-3M0\n4. ER(+) and/or PR(+).\n5. Premenopausal woman.\n6. Age\u226540 years\n7. Measurable disease as per RECIST criteria\n8. Karnofsky\u226570\n9. Labratory criteria:\n\n   * PLT\u2265100\\*109/L\n   * WBC\u22654000/mm3\n   * HGB\u226510g/dl\n   * ALT and AST\\<2\\*ULN\n\nExclusion Criteria:\n\n1. Presence of metastatic disease.\n2. Inflammatory breast cancer.\n3. Bilateral breast cancer.\n4. previous chemotherapy or hormonal therapyfor current breast neoplasm.\n5. other malignant tumor (concurrent or previous).\n6. Pregnant woman.\n7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex.\n8. Any severe systemic disease contraindicating chemotherapy.",
    "sex": "FEMALE",
    "minimumAge": "25 Years",
    "stdAges": "ADULT"
}